PAVmed Q2 2026 Earnings Call Summary

1Key Financial Results and Metrics

Net Loss: The company reported a GAAP net loss of $6.6 million for Q2 2026, an improvement from a loss of $12.3 million in the same quarter last year. The net loss attributable to PAVmed was $5.5 million, or $0.87 per share.

Non-GAAP Loss: On a non-GAAP basis, the loss was $1.7 million, or $0.27 per share.

Cash Position: Cash at June 30 was $3.8 million, not accounting for expected cash from warrant exercises related to positive EsoGuard LCD publication.

Equity Investment: The equity method investment balance was $33 million, reflecting a decrease in the market value of Lucid shares.

Operating Expenses: Non-GAAP operating expenses were $6.1 million, slightly above the previous quarter and the average of the last four quarters, primarily due to increased R&D for the Veris implantable device.

2Strategic Updates and Business Highlights

Lucid Diagnostics: Progressing on reimbursement and commercialization initiatives, with Medicare coverage as a key near-term milestone. A new positive coverage policy from LBM Concert has been adopted by multiple health plans.

Veris Health: Commercial engagement with Ohio State University is accelerating, with patient onboarding increasing. A large purchase order was secured to support ongoing commercial efforts. An FDA submission for the implantable physiologic monitor is targeted for early 2027.

Medical Device Portfolio:

PortIO: Positive first-in-human results published, demonstrating 100% device patency. The company is preparing for an FDA pre-submission meeting, with potential for a 510(k) pathway, which would expedite the regulatory process.

Octeris: Development of a multimodal endoscopic imaging platform is ongoing, with clinical validation work expected to begin soon.

3Forward Guidance and Outlook

PAVmed anticipates continued progress across its core businesses, with a focus on achieving key milestones in reimbursement for Lucid, commercial traction for Veris, and regulatory advancements for PortIO and Octeris.

The company remains committed to its diversified model, providing multiple opportunities for shareholder value enhancement.

4Bad News, Challenges, or Points of Concern

Cash Position: The current cash balance may limit operational flexibility until additional funding is secured through warrant exercises.

Market Conditions: The decline in the market value of Lucid shares poses a risk to PAVmed's equity investment and overall financial health.

Regulatory Uncertainty: While there is potential for a faster 510(k) pathway for PortIO, there remains uncertainty regarding FDA approval timelines and requirements.

5Notable Q&A Insights

FDA Meeting for PortIO: The pre-submission meeting is expected in Q4 2026, with potential regulatory pathway updates possibly extending into 2027.

Commercialization Plans: PAVmed has a clear commercialization strategy for PortIO, targeting vascular surgeons and interventional radiologists, with plans for a small sales team and distributor partnerships.

Veris Metrics: While specific patient onboarding numbers were not disclosed, the company remains on track to enroll 1,000 patients in a registry within a year, with accelerating enrollment noted.

Octeris Clinical Validation: The upcoming study will focus on validating the probe's ability to detect esophageal dysplasia, with a timeline indicating several years before potential FDA submission. Overall, PAVmed is making strides in its strategic initiatives while managing financial challenges and regulatory uncertainties.